Stay updated on INDUCE-3: GSK3359609 & Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the INDUCE-3: GSK3359609 & Pembrolizumab Clinical Trial page.

Latest updates to the INDUCE-3: GSK3359609 & Pembrolizumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new Revision: v3.4.2 has been added to the record history, replacing the previous v3.4.1. This is a minor UI/versioning update that does not affect clinical trial data or page functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is shown in the history; there are no changes to study data, status, or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe history view received minor UI updates: the glossary option is shown, additions/deletions are color-coded, and the revision label changed to v3.4.0 with No FEAR Act Data; the old v3.3.4 label was removed.SummaryDifference0.5%

- Check42 days agoChange DetectedNew revision entry: v3.3.4 appears in the page history, and v3.3.3 is removed.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page displays a new Revision: v3.3.3 and the HHS Vulnerability Disclosure footer link has been removed; the prior Revision: v3.3.2 entry was deleted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check91 days agoChange DetectedThe old version shows v3.2.0 replaced by v3.3.2 in the page header/footer; no substantive changes to study history, content, or layout are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to INDUCE-3: GSK3359609 & Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INDUCE-3: GSK3359609 & Pembrolizumab Clinical Trial page.